We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lung Cancer Gene Signatures May Predict Response to Chemotherapy

Lung Cancer Gene Signatures May Predict Response to Chemotherapy content piece image
Lung cancer driven by the Kras oncogene (purple). Credit: National Cancer Institute \ Huntsman Cancer Institute at the Univ. of Utah
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Researchers at the Francis Crick Institute have developed a method that could help predict whether people with lung cancer will respond to chemotherapy, based on which genes are switched on in their tumor.

In recent years, cancer researchers have increased our understanding of how particular gene mutations impact how a tumour develops, evolves and responds to treatment. However, the presence of mutations alone does not provide a complete picture of the tumour’s biology. 

In their study, published in Nature Communications this week, the scientists looked at expression of different genes within tumours, which ones are switched on or off. 

Focusing on genes associated with the RAS signalling pathway, the researchers analysed datasets containing information on the activity of these genes in cancer cells. From these datasets and with the help of AI, they compiled a unique gene signature of 84 genes.

When the scientists looked retrospectively at data from over 500 lung cancer patients who had already been through treatment, the gene signature was able to correctly predict which patients would have and would not have benefitted from chemotherapy.

Sophie de Carné, co-lead author and postdoctoral research scientist in the Oncogene Biology laboratory at the Crick, says: “With many cancer therapies on offer, and more drugs on trial, it is a challenge to predict which treatment has the highest chance of success for a particular patient. Because we know that RAS signalling is involved in various drug-resistance mechanisms, we hope our gene signature will help define groups of patients who could benefit from specific therapies.

“In the meantime, there is lots of work that needs to be done to reach this goal. It needs to be tested in a trial setting, and we are also adapting it to hopefully make it easier to be deployed.”

Julian Downward, co-lead author and principal group leader of the Oncogene Biology laboratory at the Crick, says: “Our work shows that the RAS signalling pathway is a crucial factor in explaining why, in lung cancer patients, there is varied response to chemotherapy. Levels of gene expression in this pathway is more decisive than the presence of certain gene mutations, including a mutation in the KRAS gene.” 

Philip East, first author and deputy head of the bioinformatics and biostatistics platform at the Crick, adds: “Thanks to advancing computational tools we can tap into the immense amount of existing data on cancer. This study shows how these datasets can lead to new insights that have the potential to improve outcomes for patients.”

The researchers will continue this work, including studying whether their gene signature could also be used to predict which patients are most likely to benefit from immunotherapy. And while this gene signature was optimised for lung cancers, the method could be used to develop signatures for other cancers.

Reference: East P, Kelly GP, Biswas D, et al. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma. Nat Commun. 2022;13(1):5632. doi:10.1038/s41467-022-33290-0

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.